anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Nicorandil
Trial phase: Phase 4
ATC code: C01DX16
SMILES: O=C(NCCO[N+](=O)[O-])c1cccnc1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: nicorandil (10mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)

Nicorandil: nicorandil (10mg tablets, two times a day)
Eligibility criteria:
Inclusion Criteria:

on coronary angiographic studies, arterial narrowing did not exceed 50% in any of the three main coronary arteries; (
a delayed opacification in at least one of the main coronary arteries was documented. Delayed opacification was defines as corrected TIMI frame count > 23 fps

Exclusion Criteria:

comorbid cardiovascular condition other than mild coronary atherosclerosis and coronary slow flow
refusal to participate
discontinuation of treatment
not returning for the follow up visit
Intervention: Methylphenidate
Trial phase: Phase 3
ATC code: N06BA04 | N06BA11 | N06BA15
SMILES: COC(=O)C(c1ccccc1)C1CCCCN1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 22
Group description: Double-blind, optimal dose of HLD200 for 7 days
Eligibility criteria:
Inclusion Criteria:

Male and female children (6-12 years at study entry)
Previous diagnosis of ADHD and confirmation using the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)
Able to swallow treatment capsules
Available for entire study period
Provision of informed consent (from the parent[s] and/or legal representative[s]) and assent (from the subject)
Female subjects of childbearing potential (i.e., post-menarche) required to have a negative result on urine pregnancy test (and will be given specific instructions for avoiding pregnancy during trial).

Exclusion Criteria:

Any known history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, ophthalmologic disease
Presence of any significant physical or organ abnormality
Any illness during the 4 weeks before this study
Comorbid psychiatric diagnosis that may affect subject safety or confound results (e.g., psychosis, bipolar disorder)
Known history of severe asthma (in the opinion of the investigator) unless deemed currently controlled
Known history of severe allergic reaction to MPH
Known history of seizures (except febrile seizures prior to age 5), anorexia nervosa, bulimia or current diagnosis or family history of Tourette's disorder
Subject who are severely underweight or overweight (in the opinion of the Investigator)
Any clinical laboratory value outside of the acceptable ranges, unless deemed NCS significant per the Investigator
Positive history for hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV)
Positive screening for illicit drug use, and/or current health conditions or use of medications that might confound the results of the study or increase risk to the subject
Use of prescription medications (except ADHD medications) within 7 days and over-the-counter medications (except birth control) within the 3 days preceding study enrollment, unless deemed acceptable by the Investigator and Clinical or Medical Monitor
Participation in clinical trial with an investigational drug within the 30 days preceding study enrollment
Current suicidal ideation or history of suicidality determined as a significant finding on the C-SSRS by the investigator (Baseline C-SSRS for adolescents; Pediatric Baseline C-SSRS for children).
Intervention: Sitagliptin
Trial phase: Phase 4
ATC code: A10BD07 | A10BD12 | A10BD24 | A10BH01 | A10BH51
SMILES: N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 28
Group description: Sitagliptin first for four weeks, then washout for four weeks, then placebo for four weeks
Eligibility criteria:
Inclusion Criteria:

Written consent has been given.
Patients with metformin treated T2DM (metformin dose >0,5 g/day and stable during the preceding 3 months)
Age >65 years.
HbA1c 6.0-8.5% (43-67 mmol/mol; inclusive) at visit 1.
Ability to complete the study

Exclusion Criteria:

A history of any secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly.
Type 2 diabetes, positive GAD antibodies
eGFR <60 ml/min
Acute infections which may affect blood glucose control within 4 weeks prior to visit 1
Any history of recent (<2 weeks) recurrent or severe hypoglycemic episodes.
Liver disease such as cirrhosis or chronic active hepatitis
History of coronary heart disease or heart failure class III or IV
Donation of one unit (500 ml) or more of blood, significant blood loss equaling to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks.
Treatment with growth hormone of chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1.
Use of other investigational drugs at visit 1 or within 30 days of visit 1, unsuitable for the study
Intervention: Midazolam
Trial phase: Not Applicable
ATC code: N05CD08
SMILES: Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 68
Group description: Intravenous 0.1 mg/kg midazolam was administered to the patients as premedication drug before entering operating room.

Midazolam: preoperatively injected intravenous 0.1 mg/kg midazolam
Eligibility criteria:
Inclusion Criteria:

American society of anesthesiologists physical status 1-2 aged 2-6 years old, who were scheduled to undergo ophthalmic surgery (<2hr)

Exclusion Criteria:

children with central nervous system disorders,history of allergy to the study drugs (midazolam and ketamine), history of recent respiratory tract infection
Intervention: Ketamine
Trial phase: Not Applicable
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 68
Group description: Intravenous 1 mg/kg ketamine was administered to the patients as premedication drug before entering operating room.

Ketamine: Preoperatively injected intravenous 1mg/kg ketamine
Eligibility criteria:
Inclusion Criteria:

American society of anesthesiologists physical status 1-2 aged 2-6 years old, who were scheduled to undergo ophthalmic surgery (<2hr)

Exclusion Criteria:

children with central nervous system disorders,history of allergy to the study drugs (midazolam and ketamine), history of recent respiratory tract infection
Intervention: Aminocaproic acid
Trial phase: Phase 4
ATC code: B02AA01
SMILES: NCCCCCC(=O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 28
Group description: An EACA loading dose of 100 mg/kg with a max of 4-5 grams will be given up to 1 hour prior to incision. During the case, an EACA infusion of 33 mg/kg/hr (max of 1 gram/hr) will be maintained. The use of EACA will be terminated at the end of the case.
Eligibility criteria:
Inclusion Criteria:

Scheduled for bilateral varus rotational osteotomy (VRO) with or without associated soft tissue and osseous procedures

Exclusion Criteria:

Preoperative use of an anticoagulant (Plavix, warfarin, lovenox, etc.)
History of hypersensitivity to EACA
History of thromboembolic event (e.g., PE or DVT)
History of renal insufficiency or failure
Congenital or acquired coagulopathy as evidence by INR >1.4 or PTT > 1.4 times normal, or Platelets <150,000/mm3 on preoperative laboratory testing
Use of hormone replacement therapy or hormonal contraceptive agents within days prior to surgery
Use of acetylsalicylic acid (ASA), antiplatelet agents within 7 days prior to surgery
Pregnant
Breastfeeding
Not received neuraxial anesthesia
Intervention: Aminocaproic acid
Trial phase: Phase 4
ATC code: B02AA01
SMILES: NCCCCCC(=O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 28
Group description: Equivalent volume of normal saline prepared by the pharmacy.
Eligibility criteria:
Inclusion Criteria:

Scheduled for bilateral varus rotational osteotomy (VRO) with or without associated soft tissue and osseous procedures

Exclusion Criteria:

Preoperative use of an anticoagulant (Plavix, warfarin, lovenox, etc.)
History of hypersensitivity to EACA
History of thromboembolic event (e.g., PE or DVT)
History of renal insufficiency or failure
Congenital or acquired coagulopathy as evidence by INR >1.4 or PTT > 1.4 times normal, or Platelets <150,000/mm3 on preoperative laboratory testing
Use of hormone replacement therapy or hormonal contraceptive agents within days prior to surgery
Use of acetylsalicylic acid (ASA), antiplatelet agents within 7 days prior to surgery
Pregnant
Breastfeeding
Not received neuraxial anesthesia
Intervention: Ethanol
Trial phase: Phase 3
ATC code: D08AX08 | V03AB16 | V03AZ01
SMILES: CCO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: 15 patients with diagnosis of severe dry eye will receive PRP injection at day 0, 30,60 and 90

PRP injection
Eligibility criteria:
Inclusion Criteria:

• Patients with symptomatic Dry eye

Shirmer ≤10 mm in 5 min
BUT ≤10 seconds
Corneal staining ≥3
Age range: 18 years and older.
Both genders and all ethnic groups comparable with the local community.
Able to understand and willing to sign a written informed consent
Able and willing to cooperate with the investigational plan.
Able and willing to complete all mandatory follow-up visits.

Exclusion Criteria:

• Patients who are currently engaged in another clinical trial, unwilling or unable to give consent, to accept randomization, or to return for scheduled visits.

Children under 18.
Pregnant women or expecting to be pregnant during the study.
Systemic immune deficient conditions such as AIDS or under systemic immunosuppressant.
Concomitant use of systemic antibiotics or steroids.
Contact lens wear
Active ocular infection or allergy
Unable to close eyes or uncontrolled blinking
Intervention: Ketoprofen
Trial phase: Phase 4
ATC code: M01AE03 | M01AE17 | M01AE53 | M02AA10 | M02AA27 | N02AJ14
SMILES: CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: Ketoprofen 225-300 mgs daily, taken orally

Ketoprofen-exploratory group: 225-300 mgs daily for four to six months
Eligibility criteria:
Inclusion Criteria:

a history of lymphedema of one or more limbs (unilateral or bilateral), with a duration of > 6 months.

Exclusion Criteria:

Patients with active cancer, infection or bleeding tendency will be excluded.
We will also exclude patients with medical contraindications to NSAIDs, including history of allergies, know gastrointestinal intolerance, or other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would impair the patients' ability to participate.
Minors (<18 years of age) *>90 years of age
Intervention: Ketoprofen
Trial phase: Phase 4
ATC code: M01AE03 | M01AE17 | M01AE53 | M02AA10 | M02AA27 | N02AJ14
SMILES: CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: Ketoprofen 225 mg daily, taken orally

Open-label group: 75 mgs, three times daily, for four months
Eligibility criteria:
Inclusion Criteria:

a history of lymphedema of one or more limbs (unilateral or bilateral), with a duration of > 6 months.

Exclusion Criteria:

Patients with active cancer, infection or bleeding tendency will be excluded.
We will also exclude patients with medical contraindications to NSAIDs, including history of allergies, know gastrointestinal intolerance, or other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would impair the patients' ability to participate.
Minors (<18 years of age) *>90 years of age
Intervention: Ketoprofen
Trial phase: Phase 4
ATC code: M01AE03 | M01AE17 | M01AE53 | M02AA10 | M02AA27 | N02AJ14
SMILES: CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: Participants randomized to receive active medication: ketoprofen 75 mgs., three times daily, taken orally

Ketoprofen: 1 capsule, three times daily, for four months
Eligibility criteria:
Inclusion Criteria:

a history of lymphedema of one or more limbs (unilateral or bilateral), with a duration of > 6 months.

Exclusion Criteria:

Patients with active cancer, infection or bleeding tendency will be excluded.
We will also exclude patients with medical contraindications to NSAIDs, including history of allergies, know gastrointestinal intolerance, or other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would impair the patients' ability to participate.
Minors (<18 years of age) *>90 years of age
Intervention: Landipirdine
Trial phase: Phase 2
SMILES: NC(=O)NC[C@@H]1CCCc2cc(S(=O)(=O)c3cccc(F)c3)ccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: SYN120: SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
Eligibility criteria:
Inclusion Criteria:

Parkinson's Disease Dementia
Patient has a routine caregiver
Taking a stable cholinesterase inhibitor.
Patient has a Montreal Cognitive Assessment (MoCA) 10-23 inclusive

Exclusion Criteria:

History of any significant neurologic or psychiatric disease other than PD
Any other condition or clinically significant abnormal findings that would make the patient unsuitable for the study
Unpredictable motor fluctuations that would interfere with administering assessments
Intervention: Acthargel
Trial phase: Not Applicable
SMILES: CSCCC(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(N)CO)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1cnc[nH]1)C(=O)NC(Cc1ccccc1)C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCC(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(Cc1ccc(O)cc1)C(=O)N1CCCC1C(=O)NC(CC(N)=O)C(=O)NCC(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(Cc1ccccc1)C(=O)N1CCCC1C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)O)C(C)C)C(C)C)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: Acthar 80 units subcutaneously for five consecutive days.

Acthar: Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.
Eligibility criteria:
Inclusion Criteria:

Subjects who have volunteered and consented to participate in the study.
Subjects who have no contraindication to taking high dose, oral prednisone or Acthar.
Male or Female subjects age 18 or greater years of age.
Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) based on 2010 McDonald Criteria.
Subjects without an active infection (Note: If a patient is found to have an uncomplicated UTI and agrees to start on appropriate antibiotic treatment, they can continue in the study).
Subjects who are experiencing a protocol defined MS relapse within two weeks of relapse onset.
Subjects who are able and willing to sign a consent form.

Exclusion Criteria:

Subjects who are less than 18 years of age.
Subjects with any contraindication to taking Acthar.
Subjects with an active infection other than an uncomplicated urinary tract infection (UTI) (subjects determined to have a UTI who agree to be treated with appropriate antibiotics will not be excluded).
Subjects with an immune deficiency.
Subjects with a history of any of the following conditions: gastrointestinal ulcers, diabetes mellitus, gestational diabetes, malignant hypertension or steroid induced psychosis.
Subjects who are pregnant or breastfeeding.
Subjects who are unable or unwilling to sign consent form.
Patient is unable or unwilling to participate in phone and clinic follow up.
Other factors that in the opinion of the Principal Investigator would exclude the subject from participation in the study.
Intervention: Lisdexamfetamine
Trial phase: Not Applicable
ATC code: N06BA12
SMILES: C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 38
Group description: Participants will be administered lisdexamfetamine, which is in tablet form, and will be instructed to take the medication daily for 6 weeks. The daily dose will range between 30 and 70mg.

Lisdexamfetamine: Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
Eligibility criteria:
Inclusion Criteria:

ADHD Participants:

The participant satisfies Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a primary diagnosis of ADHD, any subtype.

Healthy Control Participants:

The participant must have no current DSM Axis I psychiatric disorder.

All Participants:

Participants must provide assent and a legal guardian must provide consent.
The participant is male or female and between 6 - 17 years of age and in good physical health.
Girls of childbearing potential must have a negative urine pregnancy test and, if sexually active, must be using adequate contraception.
The participant is English speaking.

Exclusion Criteria:

ADHD Participants:

The participant has a current comorbid DSM Axis I psychiatric diagnosis or other symptomatic manifestations that, in the opinion of the study doctor, will contraindicate lisdexamfetamine or guanfacine treatment or confound safety assessments.
The participant meets DSM-5 criteria for current substance abuse and/or dependence.
The participant is currently taking or has taken within the past 4 months, a psychotropic medication.
The participant has a documented allergy or intolerance to lisdexamfetamine or guanfacine products.
The participant has a diagnosis or a history of cardiovascular disease or any other serious medical illness.
The participant is pregnant or lactating.
The participant is actively suicidal.
MRI contraindications (e.g., irremovable metal on the body, pacemaker, braces)
The participant has a full-scale intelligence quotient (IQ) less than 70.
The participant has a history of seizure (except febrile seizure).

Healthy Controls:

The participant meets DSM criteria for current substance abuse and/or dependence.
The participant is currently taking a psychotropic medication.
The participant has a history of a serious medical illness.
The participant is pregnant or lactating.
MRI contraindications (e.g., irremovable metal on the body, pacemaker, braces)
The participant has a full-scale intelligence quotient (IQ) less than 70.
The participant has a history of seizure (except febrile seizure).
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 83
Group description: Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.

Normal Saline: Normal Saline
Eligibility criteria:
Inclusion Criteria:

Adult (≥ 18 years)
Cardiac arrest with sustained return of spontaneous circulation (ROSC)
Comatose (i.e., not following commands) following ROSC
Undergoing targeted temperature management (TTM)
Time of enrollment ≤ 6 hours from initiation of targeted temperature management
Serum Lactate ≥2

Exclusion Criteria:

Pre-existing dementia, severe brain injury, or dependence on others for activities of daily living (i.e. a modified Rankin scale (mRS) score of 4 or higher)
Traumatic etiology of the cardiac arrest
Protected population (pregnant, prisoner)
Intervention: Pregabalin
Trial phase: Phase 4
ATC code: N02BF02 | N03AX16
SMILES: CC(C)C[C@H](CN)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 73
Group description: Pregabalin - 100 mg at bedtime for 1 week, then 100 mg 2 times per day for 1 week, then 100 mg 3 times per day for the remainder of the study.

Pregabalin
Eligibility criteria:
Inclusion Criteria:

Diagnosis of cryptogenic sensory polyneuropathy.
Likert Pain Score of greater than or equal to 4.
Must not currently be on nortriptyline, duloxetine, pregabalin or mexiletine or similar class of medication for at least 7 days from baseline study visit.

Exclusion Criteria:

Any medical condition or current medication that would prevent them from taking either nortriptyline, duloxetine, pregabalin or mexiletine.
Unable to give consent.
Unable or not willing to comply with the study.
Other causes for polyneuropathy.
Intervention: Mexiletine
Trial phase: Phase 4
ATC code: C01BB02
SMILES: Cc1cccc(C)c1OCC(C)N
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 69
Group description: Mexiletine - 200 mg at bedtime for 1 week, then 200 mg 2 times per day for 1 week, then 200 mg 3 times per day for the remainder of the study.

Mexiletine
Eligibility criteria:
Inclusion Criteria:

Diagnosis of cryptogenic sensory polyneuropathy.
Likert Pain Score of greater than or equal to 4.
Must not currently be on nortriptyline, duloxetine, pregabalin or mexiletine or similar class of medication for at least 7 days from baseline study visit.

Exclusion Criteria:

Any medical condition or current medication that would prevent them from taking either nortriptyline, duloxetine, pregabalin or mexiletine.
Unable to give consent.
Unable or not willing to comply with the study.
Other causes for polyneuropathy.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 100
Group description: Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria in Period 2, the subject will receive up to 2 open-label treatments with onabotulinumtoxinA into the protocol-specified areas.
Eligibility criteria:
Inclusion Criteria:

Moderate to severe forehead and glabellar lines
Willing to have facial photos taken

Exclusion Criteria:

Prior exposure to botulinum toxin of any serotype for any indication
Anticipated need for treatment with botulinum toxin of any serotype for any indication during the study, other than study treatment
Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis
Any facial resurfacing laser or light treatment, microdermabrasion, or superficial peels in the past 3 months
Any medium depth or deep depth facial chemical peels; facial skin resurfacing; or permanent facial make-up in the past 6 months
Any nonpermanent soft tissue fillers, or treatment with oral retinoids in the past year
Prior face lift, thread lift, eyebrow lift, or related procedures (eg, eyelid and/or eyebrow surgery)
Prior facial treatment with permanent soft tissue fillers, synthetic implants (eg, Gore-Tex®), and/or fat transplantation